Commonwealth of Pennsylvania Public School Empls Retrmt SYS Purchases 12,733 Shares of Eli Lilly and Company $LLY

Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 7.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 192,923 shares of the company’s stock after purchasing an additional 12,733 shares during the period. Eli Lilly and Company comprises approximately 0.8% of Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s investment portfolio, making the stock its 20th biggest position. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Eli Lilly and Company were worth $150,389,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of LLY. Empower Advisory Group LLC raised its holdings in shares of Eli Lilly and Company by 6.3% during the 2nd quarter. Empower Advisory Group LLC now owns 225,934 shares of the company’s stock worth $176,122,000 after buying an additional 13,415 shares in the last quarter. Foundations Investment Advisors LLC grew its position in Eli Lilly and Company by 12.7% in the second quarter. Foundations Investment Advisors LLC now owns 48,662 shares of the company’s stock valued at $37,934,000 after acquiring an additional 5,468 shares during the last quarter. Arcadia Investment Management Corp MI grew its position in Eli Lilly and Company by 64.0% in the second quarter. Arcadia Investment Management Corp MI now owns 7,023 shares of the company’s stock valued at $5,475,000 after acquiring an additional 2,740 shares during the last quarter. Jacksonville Wealth Management LLC acquired a new position in Eli Lilly and Company during the second quarter worth about $231,000. Finally, Capstone Financial Advisors Inc. lifted its holdings in shares of Eli Lilly and Company by 15.7% in the second quarter. Capstone Financial Advisors Inc. now owns 384 shares of the company’s stock worth $299,000 after acquiring an additional 52 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Cantor Fitzgerald lifted their price target on shares of Eli Lilly and Company from $925.00 to $985.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Leerink Partners raised shares of Eli Lilly and Company from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $886.00 to $1,104.00 in a research note on Monday, November 10th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft cut their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Finally, Daiwa Capital Markets cut Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price for the company. in a report on Sunday, August 17th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $999.28.

Eli Lilly and Company Stock Up 0.2%

Shares of NYSE:LLY opened at $1,024.67 on Friday. The firm has a market cap of $968.70 billion, a P/E ratio of 66.97, a P/E/G ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,033.62. The business has a fifty day simple moving average of $826.89 and a 200 day simple moving average of $780.87. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business’s revenue was up 53.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.